Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Nucleic Acids Res ; 35(2): 517-28, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17169985

RESUMEN

Glucocorticoid-induced leucine zipper (GILZ) is a 137 amino acid protein, rapidly induced by treatment with glucocorticoids (GC), characterized by a leucine zipper (LZ) domain (76-97 amino acids), an N-terminal domain (1-75 amino acids) and a C-terminal PER domain (98-137 amino acids) rich in proline and glutamic acid residues. We have previously shown that GILZ binds to and inhibits NF-kappaB activity. In the present study we used a number of mutants with the aim of defining the GILZ molecular domains responsible for GILZ/p65NF-kappaB interaction. Results, obtained by in vitro and in vivo co-immunoprecipitation (Co-IP) and by transcriptional activity experiments, indicate that GILZ homo-dimerization, through the LZ domain, as well as the C-terminal PER domain, particularly the 121-123 amino acids, are both necessary for GILZ interaction with NF-kappaB, inhibition of transcriptional activity and of IL-2 synthesis.


Asunto(s)
Factor de Transcripción ReIA/antagonistas & inhibidores , Factores de Transcripción/química , Secuencia de Aminoácidos , Animales , Sitios de Unión , Línea Celular , Dimerización , Humanos , Interleucina-2/biosíntesis , Leucina Zippers , Ratones , Modelos Moleculares , Datos de Secuencia Molecular , Mutación , FN-kappa B/antagonistas & inhibidores , FN-kappa B/metabolismo , Estructura Terciaria de Proteína , Linfocitos T/inmunología , Factor de Transcripción ReIA/metabolismo , Factores de Transcripción/metabolismo , Transcripción Genética
2.
Int J Radiat Oncol Biol Phys ; 84(3): e299-304, 2012 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-22572075

RESUMEN

PURPOSE: To evaluate outcome and toxicity of high-dose conformal radiotherapy (RT) after radical prostatectomy. METHODS AND MATERIALS: Between August 1998 and December 2007, 182 consecutive patients with positive resection margins and/or pT3-4, node-negative prostate adenocarcinoma underwent postoperative conformal RT. The prescribed median dose to the prostate/seminal vesicle bed was 66.6 Gy (range 50-70). Hormone therapy (a luteinizing hormone-releasing hormone analogue and/or antiandrogen) was administered to 110/182 (60.5%) patients with high-risk features. Biochemical relapse was defined as an increase of more than 0.2 ng/mL over the lowest postoperative prostate-specific antigen (PSA) value measured on 3 occasions, each at least 2 weeks apart. RESULTS: Median follow-up was 55.6 months (range 7.6-141.9 months). The 3- and 5-year probability of biochemical relapse-free survival were 87% and 81%, respectively. In univariate analysis, more advanced T stages, preoperative PSA values ≥10 ng/mL, and RT doses <70 Gy were significant factors for biochemical relapse. Pre-RT PSA values >0.2 ng/mL were significant for distant metastases. In multivariate analysis, risk factors for biochemical relapse were higher preoperative and pre-RT PSA values, hormone therapy for under 402 days and RT doses of <70 Gy. Higher pre-RT PSA values were the only independent predictor of distant metastases. Acute genitourinary (GU) and gastrointestinal (GI) toxicities occurred in 72 (39.6%) and 91 (50%) patients, respectively. There were 2 cases of Grade III GI toxicity but no cases of Grade IV. Late GU and GI toxicities occurred in 28 (15.4%) and 14 (7.7%) patients, respectively: 11 cases of Grade III toxicity: 1 GI (anal stenosis) and 10 GU, all urethral strictures requiring endoscopic urethrotomy. CONCLUSIONS: Postoperative high-dose conformal RT in patients with high-risk features was associated with a low risk of biochemical relapse as well as minimal morbidity.


Asunto(s)
Adenocarcinoma/radioterapia , Neoplasias de la Próstata/radioterapia , Radioterapia Conformacional/efectos adversos , Adenocarcinoma/sangre , Adenocarcinoma/patología , Adenocarcinoma/cirugía , Anciano , Análisis de Varianza , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/sangre , Estadificación de Neoplasias , Neoplasia Residual , Periodo Posoperatorio , Próstata/efectos de la radiación , Antígeno Prostático Específico/sangre , Prostatectomía , Neoplasias de la Próstata/sangre , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/cirugía , Dosificación Radioterapéutica , Estudios Retrospectivos , Vesículas Seminales/efectos de la radiación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA